ArticleChemistry & biodiversity2026
Evaluation of Uliginosin B as a Modulator of the Ras Pathway: In Vivo Evidence From Caenorhabditis elegans and In Silico Insights.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Previously, in vitro studies have suggested a possible antiproliferative action of uliginosin B (ULI B), a dimeric acylphloroglucinol isolated from Hypericum species. However, no in vivo evidence of this effect has been found yet. Therefore, the aim is to evaluate its possible interaction in the Ras pathway using the nematode Caenorhabditis elegans and computational models. For the in vivo assays, we used a strain with a gain-of-function in the let-60 gene, which is a human Ras homologous protein that leads to the formation of tumorous multivulva. The experimental tests indicated that a single 30 min treatment with ULI B was safe regarding toxicological parameters, and the worms demonstrated a delay in the multivulva phenotype development (MV) on day 1 and 2 of adulthood, with statistical significance at 5, 10, and 20 µM. In silico, ULI B showed a possible allosteric and non-competitive interaction with LET-60, but not as significant as in the human Ras, possibly justifying the weak effect found with the delay in MV development in the nematode. However, based on the in-silico data, ULI B seems promising against human cancer cells, as its interactions with EGFR and HRAS were more favorable than those with C. elegans proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.